Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
presented a late-breaking poster presentation on the positive results from the rademikibart global Phase 2b trial in patients with moderate-to-severe asthma at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024 in San Diego, CA.
- presented a late-breaking poster presentation on the positive results from the rademikibart global Phase 2b trial in patients with moderate-to-severe asthma at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024 in San Diego, CA.
- A predefined exploratory analysis showed further improvement in lung function was achieved in patients with eosinophil levels of ≥300 cells/µl.
- The Company has scheduled an EoP2 meeting with the FDA to discuss rademikibart’s Phase 3 regulatory path in Q2 2024.
- A copy of the poster presentation will be made available on Connect Biopharma’s website under the “ Our Science ” section.